Elhízás: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 170
• PPAR 0
• FTO 0
• AMPK 3
• GIP 20
• SGLT2 5
• STAT3 0
• SIRT1 0
• PI3K 0
• NRF2 0
• AKT 0
• mTOR 2
• NLRP3 3
• MAPK 0
• TP53 0
• TNF 0
• IL-6 1
• TLR4 0
• BDNF 2
• DPP-4 1
• JNK 0
• APOE 0
• ERK 0
• IL-17 1
• PTEN 0
• STING 0
• ACE2 0
• HIF-1 0
• PCSK9 0
• VEGF 0
• IL-1 0
• JAK 0
• PNPLA3 2
• YAP 0
• HMGB1 0
• CTNNB1 0
• HER2 0
• MMP-9 0
• PD-L1 0
• PINK1 0
• TFEB 0
• TREM2 0
• CCR5 0
• FGFR 0
• GPX4 0
• IGF1R 0
• IL-23 0
• METTL3 0
• PD-1 0
• STK11 0
• AR 0
• BCL-2 0
• CFTR 0
• COX-2 0
• HDAC 0
• EGFR 0
• HSP90 0
• MEK 0
• MYC 0
• PKM2 0

30+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the role of maternal nutrient stores in the metabolism of the preimplantation embryo (MaterMeta)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the role of Tbx-3 expressing neurons during obesity and ageing (OBrAgeing)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 226 421 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Selective Sensory Vagal Interface: a bionic platform for internal organ modulation (VisceraLink)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 2 210 625 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Metabolic disease heterogeneity definition, prevention and remission with targeted interventions (MEDIculous REMeDy)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Németország· EU contribution 4 437 236 EUR· until 2030. dec.· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Svájc· EU contribution 3 885 022 EUR· until 2030. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 127 running projects, newest first. Listed amounts together: 430,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Frissítve: 2026. okt. 16.

  “poor accrual and funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

  NCT07553299· Verdiva Bio Dev Limited· Frissítve: 2026. okt. 13.

  “The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  RESCUE: Discontinuation of GLP-1

  NCT07190794· Boston Scientific Corporation· Frissítve: 2026. júl. 24.

  “Business decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Frissítve: 2026. júl. 13.

  “no grant approved”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change

  NCT07097974· TCI Co., Ltd.· Frissítve: 2026. máj. 13.

  “based on an overall assessment of feasibility and strategic considerations”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

  NCT06171152· University of Chicago· Frissítve: 2026. márc. 30.

  “Study pending amendment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  The Effects of Semaglutide on Body Composition and Performance in Military Personnel

  NCT06468748· United States Army Research Institute of Environmental Medicine· Frissítve: 2025. dec. 19.

  “lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

  NCT06000891· Zealand Pharma· Frissítve: 2025. ápr. 25.

  “Decision by Sponsor; LSLV was completed on 21-Mar-2025 as planned.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

  NCT06515418· BioAge Labs, Inc.· Frissítve: 2025. márc. 13.

  “Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

  NCT04885634· Axel Brandes· Frissítve: 2023. nov. 3.

  “Not received funding.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

  NCT07517042· Shanghai Zhongshan Hospital· Forrás

• 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor

  NCT07929233· Portuguese Oncology Institute, Coimbra· Forrás

• Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

  NCT07830329· Regeneron Pharmaceuticals· Forrás

• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

  NCT06162715· Vanderbilt University Medical Center· Forrás

• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

  NCT07775404· AstraZeneca· Forrás

• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Amgen· Forrás

• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  NCT07685808· Regeneron Pharmaceuticals· Forrás

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Pfizer· Forrás

• A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

  NCT06973720· Pfizer· Forrás

• A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Pfizer· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 21
• Organoids 10
• Mendelian Randomization Analysis 179
• CRISPR-Cas Systems 7
• Gene Expression Profiling 144
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 4
• Exome Sequencing 19
• Proteomics 127
• Metabolomics 190
• Mass Spectrometry 28
• Flow Cytometry 16
• Immunohistochemistry 41
• Xenograft Model Antitumor Assays 15
• Positron-Emission Tomography 25
• Magnetic Resonance Imaging 258
• Machine Learning 155
• Deep Learning 20
• Cohort Studies 1013
• Genome-Wide Association Study 202

• Single-cell landscape of human adipose tissue reveals THBS1 as a potential driver of fibro-inflammation in metabolic disease.

  Nat Commun, 2026. okt.

• Single-cell transcriptomics uncovers persistent hepatic immunometabolic remodeling following SARS-CoV-2 infection in obese hosts.

  Front Immunol, 2026. okt.

• Single-cell RNA sequencing reveals a pro-fibrotic epithelial subpopulation contributing to endometrial dysfunction in polycystic ovary syndrome.

  Front Endocrinol (Lausanne), 2026. szept.

• Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes.

  Diabetologia, 2026. szept.

• Single-cell profiling identifies obesity-disrupted brain glucose sensing.

  Nat Commun, 2026. aug.

• Female-specific metabolic genetic liability reveals a separable metabolic dimension of polycystic ovary syndrome.

  Mol Cell Endocrinol, 2026. júl.

• Alterations of sphingosine-1-phosphate and its receptors in type 1 diabetes mellitus: an integrated clinical and single-cell transcriptomic study.

  Front Immunol, 2026. jún.

• Temporal single-cell transcriptional dynamics of murine pancreatic islet remodeling during hyperglycaemia progression.

  Mol Metab, 2026. jún.

• Single-Cell Transcriptome-Wide Mendelian Randomization and Colocalization Uncover Potential Immunocytes-Related Therapeutic Targets for Obesity.

  J Cell Mol Med, 2026. máj.

• Adipose single cell epigenome and transcriptome localize genetic risk for cardiometabolic disease and accelerated aging.

  Nat Commun, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.